A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma
Status:
Terminated
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 clinical trial to collect data on tumor responses produced by folate-hapten
conjugate therapy (vaccination with EC90 [KLH-FITC] and GPI-0100 adjuvant followed by
treatment with EC17 (folate-FITC) in combination with low-dose cytokines in patients with
progressive metastatic renal cell carcinoma. All patients will undergo imaging with the
investigational imaging agent 99mTc-EC20 (FolateScan) during the screening period to confirm
eligibility for the treatment portion of the clinical trial.
Phase:
Phase 2
Details
Lead Sponsor:
Endocyte
Treatments:
Folic Acid Interferon-alpha Interferons Interleukin-2 Keyhole-limpet hemocyanin Vitamin B Complex